“The pandemic year of 2020 was exceptional and very challenging for Sartorius Stedim Biotech as well. Our strong business results once again underscore the strength and resilience of our strategy and business model. In this demanding environment, we were able to both achieve very substantial growth and close a few strategically very relevant acquisitions. And more than that: We are an essential contributor toward overcoming this pandemic; each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world.”
Sartorius Stedim Biotech recorded exceptionally dynamic growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. The Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, recording further gains across all geographies.